MyoKardia

M&A landscape is tilting away from late-stage buys and toward a platform strategy: analysts
Fierce Pharma
Tue, 06/28/22 - 10:45 am
M&A
Accenture
Bristol Myers Squibb
MyoKardia
ACC 2022 – Bristol's rare hit could justify Myokardia
EP Vantage
Sat, 04/2/22 - 11:38 am
ACC
Bristol Myers Squibb
MyoKardia
hypertrophic cardiomyopathy
mavacamten
BMS builds case for mavacamten label ahead of FDA decision
Pharmaforum
Thu, 02/17/22 - 11:01 am
Bristol Myers Squibb
mavacamten
obtructive hypertrophic cardiomyopathy
MyoKardia
FDA
A couple months ahead of its PDUFA data, Bristol Myers rolls out long-term data for mavacamten
Endpoints
Sat, 11/13/21 - 09:57 pm
Bristol Myers Squibb
FDA
mavacamten
MyoKardia
The top 10 largest biopharma M&A deals in 2020
Fierce Pharma
Tue, 01/19/21 - 10:30 am
M&A
AstraZeneca
Alexion
Bristol-Myers Squibb
MyoKardia
Gilead Sciences
Forty Seven
Merck
VelosBio
Nestle
Aimmune
Immunomedics
JNJ
Momenta Pharmaceuticals
Sanofi
Principia Biopharma
Bayer
Asklepios BioPharmaeutical
Astrazeneca shows megamergers were still possible in 2020
EP Vantage
Wed, 01/6/21 - 10:41 am
M&A
AstraZeneca
Alexion
Bristol-Myers Squibb
MyoKardia
Bayer
Asklepios
Merck
VelosBio
Gilead Sciences
Forty Seven
Immunomedics
JNJ
Momenta
Bristol Myers Squibb Closes $13.1 Billion Acquisition of MyoKardia
Motley Fool
Tue, 11/17/20 - 11:11 pm
Bristol-Myers Squibb
MyoKardia
M&A
[video+transcript]Here's What's Behind Bristol Myers Squibb's Huge Acquisitions
Motley Fool
Wed, 11/4/20 - 10:12 am
Bristol-Myers Squibb
M&A
Celgene
MyoKardia
Pharmacquired: Splashy deals belie a shallow pool of heart drugs left to acquire
BioPharma Dive
Thu, 10/8/20 - 11:16 pm
M&A
cardiology
Bristol-Myers Squibb
MyoKardia
Novartis
The Medicines Company
Here's Why Bristol Myers Offered MyoKardia $13.1 Billion
Motley Fool
Wed, 10/7/20 - 10:52 am
M&A
MyoKardia
Bristol-Myers Squibb
Bristol Myers to buy MyoKardia in $13B bet on targeted drugs for the heart
BioPharma Dive
Mon, 10/5/20 - 11:52 am
Bristol-Myers Squibb
M&A
MyoKardia
genetic heart disease
MyoKardia’s Heart Drug Shines in Phase 3, FDA Filing Planned for 2021
Xconomy
Mon, 05/11/20 - 11:46 pm
MyoKardia
clinical trials
mavacamten
obstructive hypertrophic cardiomyopathy
Myokardia at inflection point as heart drug readout nears
BioPharma Dive
Thu, 04/9/20 - 10:40 am
MyoKardia
clinical trials
heart disease
mavacamten
Safety qualms in MyoKardia mid-stage study cause investors to pause
Endpoints
Tue, 11/12/19 - 09:49 am
MyoKardia
obstructive hypertrophic cardiomyopathy
clinical trials
mavacamten
MyoKardia cuts all ties to Sanofi
Biopharma Dive
Thu, 07/18/19 - 05:52 pm
MyoKardia
MYK-224
Sanofi
obstructive hypertrophic cardiomyopathy
mavacamten
MyoKardia raises $251.2M in follow-on
BioCentury
Wed, 03/27/19 - 10:17 am
MyoKardia
mavacamten
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs
Yahoo/Benzinga
Sun, 03/3/19 - 07:09 pm
IPOs
biotech
JNJ
Janssen
esketamine
Shockwave Medical
earnings
Sensen Bio
MyoKardia
Sanofi walks away from MyoKardia heart drug partnership, long before key data readout
Endpoints
Wed, 01/2/19 - 10:01 am
Sanofi
MyoKardia
mavacamten
obstructive hypertrophic cardiomyopathy
MyoKardia Heart Drug Boosts Blood Flow, Sends Shares Soaring
Xconomy
Mon, 08/7/17 - 10:00 pm
MyoKardia
hypertrophic cardiomyopathy
mavacamten
FierceBiotech's 2015 Fierce 15
Fierce Biotech
Wed, 09/30/15 - 09:51 am
Alector
Arvinas
Cell Medica
CRISPR Therapeutics
Denali Therapeutics
Intellia Therapeutics
MyoKardia
NGM Biopharmaceuticals
Padlock Therapeutics
Revolution Medicines SQZ Biotech
Surface Oncology
Syros Pharmaceuticals
Unum Therapeutics
Yumanity Therapeutics

Pages